Suppression of azoxymethane-induced colonic preneoplastic lesions in rats by 1-methyltryptophan, an inhibitor of indoleamine 2,3-dioxygenase

Cancer Science

Volumn 103, Issue 5, 2012, Pages 951-958

  Ogawa, Kengo ^a   Hara, Takeshi ^a   Shimizu, Masahito ^a   Ninomiya, Soranobu ^a   Nagano, Junji ^a   Sakai, Hiroyasu ^a   Hoshi, Masato ^a   Ito, Hiroyasu ^a   Tsurumi, Hisashi ^a   Saito, Kuniaki ^b   Seishima, Mitsuru ^a   Tanaka, Takuji ^c   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c Tohkai Cytopathology Institute: Cancer Research and Prevention   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLTRYPTOPHAN; AZOXYMETHANE; BETA CATENIN; CYCLOOXYGENASE 2; DRINKING WATER; EPIGALLOCATECHIN GALLATE; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; MESSENGER RNA; UNCLASSIFIED DRUG;

ABERRANT CRYPT FOCUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL FREE SYSTEM; COLON CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TEA; TREATMENT DURATION; UPREGULATION;

ANIMALS; ANTICARCINOGENIC AGENTS; AZOXYMETHANE; CARCINOGENS; COLONIC NEOPLASMS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MALE; PRECANCEROUS CONDITIONS; RATS; RATS, INBRED F344; TRYPTOPHAN;

EID: 84862808949     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02237.x     Document Type: Article

References (52)

1. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6: 715-27.
2. Uyttenhove C, Pilotte L, Theate I et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med 2003; 9: 1269-74.
3. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4: 762-74.
4. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J Exp Med 2002; 196: 459-68.
5. Okamoto A, Nikaido T, Ochiai K et al. Indoleamine 2, 3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 2005; 11: 6030-9.
6. Ino K, Yoshida N, Kajiyama H et al. Indoleamine 2, 3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer 2006; 95: 1555-61.
7. Brandacher G, Perathoner A, Ladurner R et al. Prognostic value of indoleamine 2, 3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 2006; 12: 1144-51.
8. Ninomiya S, Hara T, Tsurumi H et al. Indoleamine 2, 3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol 2010; 90: 409-16.
9. Yoshikawa T, Hara T, Tsurumi H et al. Serum concentration of l-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Eur J Haematol 2010; 84: 304-9.
10. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005; 11: 312-9.
11. Hou DY, Muller AJ, Sharma MD et al. Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007; 67: 792-801.
12. Lob S, Konigsrainer A, Rammensee HG, Opelz G, Terness P. Inhibitors of indoleamine-2, 3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer 2009; 9: 445-52.
13. Yang CS, Maliakal P, Meng X. Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 2002; 42: 25-54.
14. Yang CS, Wang X, Lu G, Picinich SC. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer 2009; 9: 429-39.
15. Shimizu M, Deguchi A, Lim JT, Moriwaki H, Kopelovich L, Weinstein IB. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res 2005; 11: 2735-46.
16. Shimizu M, Deguchi A, Joe AK, McKoy JF, Moriwaki H, Weinstein IB. EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells. J Exp Ther Oncol 2005; 5: 69-78.
17. Shimizu M, Deguchi A, Hara Y, Moriwaki H, Weinstein IB. EGCG inhibits activation of the insulin-like growth factor-1 receptor in human colon cancer cells. Biochem Biophys Res Commun 2005; 334: 947-53.
18. Shirakami Y, Shimizu M, Tsurumi H, Hara Y, Tanaka T, Moriwaki H. EGCG and polyphenon E attenuate inflammation-related mouse colon carcinogenesis induced by AOM and DSS. Mol Med Report 2008; 1: 355-61.
19. Shimizu M, Shirakami Y, Sakai H et al. (-)-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male C57BL/KsJ-db/db mice. Cancer Prev Res 2008; 1: 298-304.
20. Pretlow TP, O'Riordan MA, Somich GA, Amini SB, Pretlow TG. Aberrant crypts correlate with tumor incidence in F344 rats treated with azoxymethane and phytate. Carcinogenesis 1992; 13: 1509-12.
21. Bird RP. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 1995; 93: 55-71.
22. Xiao H, Hao X, Simi B et al. Green tea polyphenols inhibit colorectal aberrant crypt foci (ACF) formation and prevent oncogenic changes in dysplastic ACF in azoxymethane-treated F344 rats. Carcinogenesis 2008; 29: 113-9.
23. Jeong YI, Jung ID, Lee JS, Lee CM, Lee JD, Park YM. (-)-Epigallocatechin gallate suppresses indoleamine 2, 3-dioxygenase expression in murine dendritic cells: evidences for the COX-2 and STAT1 as potential targets. Biochem Biophys Res Commun 2007; 354: 1004-9.
24. Cheng CW, Shieh PC, Lin YC et al. Indoleamine 2, 3-dioxygenase, an immunomodulatory protein, is suppressed by (-)-epigallocatechin-3-gallate via blocking of gamma-interferon-induced JAK-PKC-delta-STAT1 signaling in human oral cancer cells. J Agric Food Chem 2010; 58: 887-94.
25. Yamada Y, Yoshimi N, Hirose Y et al. Sequential analysis of morphological and biological properties of beta-catenin-accumulated crypts, provable premalignant lesions independent of aberrant crypt foci in rat colon carcinogenesis. Cancer Res 2001; 61: 1874-8.
26. Shimizu M, Sakai H, Shirakami Y et al. Preventive effects of (-)-epigallocatechin gallate on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db mice. Cancer Prev Res 2011; 4: 396-403.
27. Wang ZY, Agarwal R, Bickers DR, Mukhtar H. Protection against ultraviolet B radiation-induced photocarcinogenesis in hairless mice by green tea polyphenols. Carcinogenesis 1991; 12: 1527-30.
28. Moolenbeek C, Ruitenberg EJ. The "Swiss roll": a simple technique for histological studies of the rodent intestine. Lab Anim 1981; 15: 57-9.
29. Bird RP. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 1987; 37: 147-51.
30. Suzuki R, Kohno H, Yasui Y et al. Diet supplemented with citrus unshiu segment membrane suppresses chemically induced colonic preneoplastic lesions and fatty liver in male db/db mice. Int J Cancer 2007; 120: 252-8.
31. Sakai H, Yamada Y, Shimizu M, Saito K, Moriwaki H, Hara A. Genetic ablation of Tnfalpha demonstrates no detectable suppressive effect on inflammation-related mouse colon tumorigenesis. Chem Biol Interact 2010; 184: 423-30.
32. Hoshi M, Saito K, Hara A et al. The absence of IDO upregulates type I IFN production, resulting in suppression of viral replication in the retrovirus-infected mouse. J Immunol 2010; 185: 3305-12.
33. Suzuki Y, Suda T, Furuhashi K et al. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer 2010; 67: 361-5.
34. Fujigaki S, Saito K, Sekikawa K et al. Lipopolysaccharide induction of indoleamine 2, 3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism. Eur J Immunol 2001; 31: 2313-8.
35. Fujigaki S, Saito K, Takemura M et al. The l-Tryptophan-l-kynurenine pathway metabolism accelerated by Toxoplasma gondii infection is abolished in gamma interferon-gene-deficient mice: cross-regulation between inducible nitric oxide synthase and indoleamine-2, 3-dioxygenase. Infect Immun 2002; 70: 779-86.
36. Shimizu M, Shirakami Y, Iwasa J et al. Supplementation with branched-chain amino acids inhibits azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db mice. Clin Cancer Res 2009; 15: 3068-75.
37. Yasuda Y, Shimizu M, Shirakami Y et al. Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Cancer Sci 2010; 101: 1701-7.
38. Katz JB, Muller AJ, Prendergast GC. Indoleamine 2, 3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 2008; 222: 206-21.
39. Dolusic E, Larrieu P, Moineaux L et al. Tryptophan 2, 3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators. J Med Chem 2011; 54: 5320-34.
40. Carlin JM, Borden EC, Sondel PM, Byrne GI. Interferon-induced indoleamine 2, 3-dioxygenase activity in human mononuclear phagocytes. J Leukoc Biol 1989; 45: 29-34.
41. Takikawa O, Tagawa Y, Iwakura Y, Yoshida R, Truscott RJ. Interferon-gamma-dependent/independent expression of indoleamine 2, 3-dioxygenase. Studies with interferon-gamma-knockout mice. Adv Exp Med Biol 1999; 467: 553-7.
42. 2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition. Blood 2006; 108: 228-37.
43. Basu GD, Tinder TL, Bradley JM et al. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J Immunol 2006; 177: 2391-402.
44. Shimizu K, Kinouchi Shimizu N, Hakamata W, Unno K, Asai T, Oku N. Preventive effect of green tea catechins on experimental tumor metastasis in senescence-accelerated mice. Biol Pharm Bull 2010; 33: 117-21.
45. Chung KT, Gadupudi GS. Possible roles of excess tryptophan metabolites in cancer. Environ Mol Mutagen 2011; 52: 81-104.
46. Koblish HK, Hansbury MJ, Bowman KJ et al. Hydroxyamidine inhibitors of indoleamine-2, 3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther 2010; 9: 489-98.
47. + T cells triggers indoleamine 2, 3-dioxygenase activity in dendritic cells. J Immunol 2004; 172: 4100-10.
48. Raju J. Azoxymethane-induced rat aberrant crypt foci: relevance in studying chemoprevention of colon cancer. World J Gastroenterol 2008; 14: 6632-5.
49. Gupta AK, Pretlow TP, Schoen RE. Aberrant crypt foci: what we know and what we need to know. Clin Gastroenterol Hepatol 2007; 5: 526-33.
50. Mori H, Hata K, Yamada Y, Kuno T, Hara A. Significance and role of early-lesions in experimental colorectal carcinogenesis. Chem Biol Interact 2005; 155: 1-9.
51. Yasui Y, Suzuki R, Kohno H et al. 9trans, 11trans conjugated linoleic acid inhibits the development of azoxymethane-induced colonic aberrant crypt foci in rats. Nutr Cancer 2007; 59: 82-91.
52. Eleftheriadis T, Antoniadi G, Liakopoulos V, Stefanidis I, Galaktidou G. Plasma indoleamine 2, 3-dioxygenase concentration is increased in hemodialysis patients and may contribute to the pathogenesis of coronary heart disease. Renal Fail 2012; 34: 68-72.